Cancer Research Technology
Log in Register
Menu

Anti-CLEC2 [AYP2]

Invented at University Of Birmingham

Info

Catalogue Number 151914
Applications WB
Antigen/Gene or Protein Targets C-type lectin-like receptor 2, CLEC1b
Reactivity Human papilloma virus
Relevance Patients with rheumatoid arthritis, an inflammatory disease associated with increased microparticle production, have raised plasma levels of microparticles that expressed CLEC-2 but not GPVI. CLEC-2 can be used to monitor platelet-derived microparticles. The observation that microparticles derived from activated platelets retain CLEC-2 but lose GPVI highlights the potential use of measurement of surface expression of platelet receptors to screen for platelet activation in a wide variety of cardiovascular and inflammatory diseases.
Host Mouse
Immunogen A recombinant extracellular fragment of human CLEC-2 (aa 68-229), which is the extracellular domain of the protein.
Positive Control Platelets
Subclass IgG1
Molecular Weight (kDa) 26
Myeloma Used Sp2/0-Ag14
Recommended Growing Conditions Hybridomas were cultured at 37ยบ C and 96% relative humidity in air containing 6% CO2. Cells were grown in complete DMEM + Pen/strep + FCS was used at 10%. Cell density: Cells should be kept between 1-2x105 cells/ml and 5x105 cells/ml.
Notes Molecular Weight- Western blotting: 32 and 40 kDa doublet from lysates as CLEC-2 is glycosylated.
Research Area Cardiovascular, Immunology

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Gitz et al. 2014. Blood. 124(14):2262-70. PMID: 25150298.

CLEC-2 expression is maintained on activated platelets and on platelet microparticles.

Europe PMC ID: 25150298


Add a reference

References: 2 entries

Gitz et al. 2014. Blood. 124(14):2262-70. PMID: 25150298.

CLEC-2 expression is maintained on activated platelets and on platelet microparticles.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor